Checkmate Pharmaceuticals, Inc. reported unaudited earnings result for the first quarter ended March 31, 2021. For the quarter, the company reported loss from operations of $14.181 million against $7.823 million a year ago. Net loss was $14.128 million against $7.801 million a year ago. Net loss per basic and diluted share attributable to common stockholders was $0.65 against $6.45 a year ago.